Success Metrics

Clinical Success Rate
80.0%

Based on 4 completed trials

Completion Rate
80%(4/5)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(17%)

Phase Distribution

Ph phase_2
1
17%
Ph phase_1
5
83%

Phase Distribution

5

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
5(83.3%)
Phase 2Efficacy & side effects
1(16.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(4)
Terminated(1)
Other(1)

Detailed Status

Completed4
unknown1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
80.0%
Most Advanced
Phase 2

Trials by Phase

Phase 15 (83.3%)
Phase 21 (16.7%)

Trials by Status

unknown117%
terminated117%
completed467%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_1

A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL

NCT04049825
completedphase_1

Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia

NCT03197714
completedphase_1

Safety and Biomarker of OPB-111077 in Subjects With Advanced Solid Tumor

NCT02250170
unknownphase_2

Phase IIa Dose-Expansion and Biomarker Study of OPB-111077

NCT03158324
terminatedphase_1

A Phase I, Open Label, Non Randomized, Multicenter, Dose Escalation Clinical Study to Investigate Safety and Tolerability of OPB(Otsuka Pharmaceutical Biwa)-111077 in Subjects With Advanced HCC(Hepatocellular Carcinoma)

NCT01942083
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT04049825Phase 1

A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL

Completed
NCT03197714Phase 1

Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia

Completed
NCT02250170Phase 1

Safety and Biomarker of OPB-111077 in Subjects With Advanced Solid Tumor

Completed
NCT03158324Phase 2

Phase IIa Dose-Expansion and Biomarker Study of OPB-111077

Unknown
NCT01942083Phase 1

A Phase I, Open Label, Non Randomized, Multicenter, Dose Escalation Clinical Study to Investigate Safety and Tolerability of OPB(Otsuka Pharmaceutical Biwa)-111077 in Subjects With Advanced HCC(Hepatocellular Carcinoma)

Terminated
NCT01711034Phase 1

A Phase 1, Open-label, Multiple Dose Escalation Trial to Determine Safety and Tolerability of Once Daily OPB-111077 in Subjects With Advanced Cancer

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6